Tumor Targeted Lymphocyte Summit 2018

Topics

• Methods to streamline the manufacture of TIL and CTL therapies to reduce cost and time expenditure
• The current clinical and translational landscape to improve upon your clinical pipeline design
• Innovative strategies to genetically engineer TIL and CTL cells to enhance cell function
• Novel biomarkers to help select a specific, tumor-reactive, cell population and predict patient response
• The potential benefits and clinical outcomes of reduced IL-2 and preconditioning therapy